House Energy & Commerce Committee Opens Vioxx Investigation
This article was originally published in The Pink Sheet Daily
Executive Summary
The House Energy & Commerce Committee has opened its investigation into the withdrawal of Vioxx with letters to FDA and Merck
You may also be interested in...
FDA Focus Will Be Phase IV Commitments Amidst "Safety Cloud," GSK Says
In light of the current "safety cloud," FDA may have an increasing focus on Phase IV commitments, GlaxoSmithKline said
FDA Focus Will Be Phase IV Commitments Amidst "Safety Cloud," GSK Says
In light of the current "safety cloud," FDA may have an increasing focus on Phase IV commitments, GlaxoSmithKline said
Sen. Grassley Wants "Independent" Drug Safety Function In FDA
Finance Committee chairman urges structural change at FDA during hearing on Merck's withdrawn COX-2 inhibitor Vioxx. Ranking Democrat Baucus says idea "makes sense;" FDA's Kweder tells the committee she personally has no objection to an independent safety office.